NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN
OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA, CANADA,
HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR
RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY
OF THE SECURITIES DESCRIBED HEREIN.  

Reference is made to the stock exchange announcement published by SoftOx
Solution AS (the "Company") earlier today, 26th of August 2024, regarding the
preliminary results of the rights issue (the "Rights Issue").  

The following primary insiders and close associates to primary insiders have
been allocated new shares in the Rights Issue: 

Henrik Nielsen, Board Member of SoftOx Solutions has been allocated 20 000 000
shares in the Right Issue. As a result, Henrik Nilsen together with his
wholly-owned company HJN Holding 2 Aps holds 26.938.485 shares in the company. 

Ulrik Spork, incoming Chairman of the Board, has been allocated 10 000 000
shares. As a result, Ulrik Spork holds 10 000 000 shares in the company. 

Thomas Bjarnsholt, Incoming Chief Executive Officer, has been allocated 7 000
000 shares. As a result, Thomas Bjarnsholt, together with his wholly owned
company Medical Consulting APS holds 10 610 505 shares in the company. 

Bonica AS, a company owned by Ingrid Juven, the ICFO in the Company, has been
allocated 10 000 000 shares in the Company. Ingrid Juven has sold 70 000 shares
in the Company. As a result, Ingrid Juven together with her fully owned company
Bonica AS holds 17 500 000 shares in the Company. 


For any questions please contact:  

Geir Almås, Chair of SoftOx Solutions AS  

Mail: ir@soft-ox.com  

Phone: Geir Almås: (+47) 977 59 071  

About SoftOx Solutions AS  

SoftOx Solutions AS (SoftOx) is a Medtech, and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes the holding
company SoftOx Solutions AS, the Malmö subsidiary Water Innovation AB, and
subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx is
developing a highly effective antimicrobial solution for use in biofilm, viral,
and antimicrobial-resistant infections. The patent-protected technology is based
on extensive research and development in partnership with leading Nordic
research institutes. 

For more information on SoftOx, visit www.soft-ox.com